• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Altimmune, Inc. - Common Stock (NQ:ALT)

1.330 -0.080 (-5.67%)
Delayed Quote Updated: 4:00 PM EST, Nov 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,058,922
Open 1.370
Bid (Size) 1.350 (700)
Ask (Size) 1.360 (3,300)
Prev. Close 1.410
Today's Range 1.320 - 1.460
52wk Range 1.320 - 6.440
Shares Outstanding 194,474,154
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Altimmune (ALT) Q3 2026 Earnings Call Transcript ↗
November 12, 2026
Spending is rising fast as the pemvidutide Phase 3 programs move forward. 
Via The Motley Fool
Topics Earnings
News headline image
What Altimmune (ALT) Said on Its Q3 Earnings Call ↗
November 12, 2026
Altimmune (NASDAQ:ALT) is ramping up a late-stage trial of its experimental drug pemvidutide for a serious liver disease and preparing for a December meeting with the U.S. Food and Drug Administration... 
Via MarketBeat
Topics Earnings

Performance

52-Week Range 79.3% below 52-week high
1.330
1.3252W Low 6.4452W High
1 Week 20.4% below 1-week high
1.321W Low 1.671W High

Altimmune, Inc. - Common Stock (ALT) traded between $1.32 and $6.44 over the past 52 weeks and last traded at $1.33, 79.3% below its 52-week high. Over the past week it ranged between $1.32 and $1.67.

Past 12 Months
-14.7%
-40.4%
-57.2%
-54.1%
-62.1%
-70.2%
1W -$0.23
1M -$0.90
3M -$1.78
6M -$1.57
YTD -$2.18
1Y -$3.14

ALT was -70.2% over the past year, -54.1% over six months, -62.1% year to date, -14.7% in the last week.

12 Months vs Market
ALT
-70.2%
DIA
+5.0%
SPY
+5.7%
QQQ
+3.9%
IWM
+12.0%

Over the past 12 months ALT returned -70.2% versus DIA (Dow) +5.0%, SPY (S&P 500) +5.7%, QQQ (Nasdaq 100) +3.9% and IWM (Russell 2000) +12.0%.

Volume & Liquidity 1.03× 3-mo avg
Today 4,058,922 3-mo avg 3.9M
1W
4.7M
1M
4.1M
3M
3.9M
6M
4.1M
YTD
4.3M
1Y
4.3M

ALT most recently traded 4,058,922 shares against a 3-month average daily volume of 3.9M.

More News

Read More
News headline image
Federal Peptide Policy Shift Could Ignite a New Wave Of Growth Across the $164 Billion Peptide Market
November 05, 2026
From FN Media
Via GlobeNewswire
Altimmune Inc (NASDAQ:ALT) Reports Q4 Earnings Miss Amid Key Pipeline Milestones ↗
March 05, 2026
Via Chartmill
Topics Earnings
News headline image
Federal Peptide Policy Shift Could Ignite a New Wave Of Growth Across The $164 Billion Peptide Market
November 05, 2026
Via FinancialNewsMedia
News headline image
Altimmune Details Pemvidutide’s Path Toward a Liver-Disease Franchise ↗
October 01, 2026
Via MarketBeat
News headline image
Altimmune Q2 Earnings Call Highlights ↗
August 12, 2026
Via MarketBeat
Topics Artificial Intelligence Earnings
News headline image
Altimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial ↗
July 28, 2026
Via MarketBeat
News headline image
Altimmune Sets Pemvidutide’s Phase 3 MASH Playbook as AUD Data Near ↗
June 10, 2026
Via MarketBeat
News headline image
Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial ↗
June 04, 2026
Via MarketBeat
News headline image
Altimmune (ALT) Q1 2026 Earnings Transcript ↗
May 13, 2026
Via The Motley Fool
News headline image
Altimmune Q1 Earnings Call Highlights ↗
May 13, 2026
Via MarketBeat
Topics Earnings
InvestorNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation
May 13, 2026
Via Investor Brand Network
News headline image
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
May 13, 2026
From BioMedWire
Via GlobeNewswire
What's going on in today's pre-market session ↗
April 23, 2026
Via Chartmill
Stay updated with the stocks that are on the move in today's after-hours session. ↗
April 22, 2026
Via Chartmill
News headline image
ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns ↗
March 05, 2026
Via Stocktwits
News headline image
Altimmune (ALT) Q4 2025 Earnings Call Transcript ↗
March 05, 2026
Via The Motley Fool
Topics Earnings
News headline image
Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play ↗
February 26, 2026
Via The Motley Fool
News headline image
Nasdaq, S&P 500 Futures Edge Higher Ahead Of Fed Decision, Mag 7 Earnings Kick Off: Why NVDA, ASML, ALT, AI, UUU Are On Traders' Radar Today ↗
January 28, 2026
Via Stocktwits
Topics Artificial Intelligence ETFs Economy
News headline image
ALT Stock Surges Toward Sixth Straight Day Of Gains: Retail Bets A Buyout Is On The Horizon ↗
January 27, 2026
Via Stocktwits
News headline image
Nasdaq, S&P 500 Futures Subdued Ahead Of PMI Data: Why INTC, TSLA, NFLX, VST, MOVE Are On Traders' Radar Today ↗
January 23, 2026
Via Stocktwits
Topics ETFs Government Lawsuit
News headline image
ALT Stock Rallies 4% — What Does Retail Think? ↗
January 22, 2026
Via Stocktwits
News headline image
Why Are Investors Looking At Altimmune Stock? ↗
January 05, 2026
Via Benzinga
News headline image
Altimmune Receives FDA’s Breakthrough Therapy Designation For Its Liver Disease Drug ↗
January 05, 2026
Via Stocktwits

Frequently Asked Questions

Is Altimmune, Inc. - Common Stock publicly traded?
Yes, Altimmune, Inc. - Common Stock is publicly traded.
What exchange does Altimmune, Inc. - Common Stock trade on?
Altimmune, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Altimmune, Inc. - Common Stock?
The ticker symbol for Altimmune, Inc. - Common Stock is ALT on the Nasdaq Stock Market
What is the current price of Altimmune, Inc. - Common Stock?
The current price of Altimmune, Inc. - Common Stock is 1.330
When was Altimmune, Inc. - Common Stock last traded?
The last trade of Altimmune, Inc. - Common Stock was at 11/20/26 04:00 PM ET
What is the market capitalization of Altimmune, Inc. - Common Stock?
The market capitalization of Altimmune, Inc. - Common Stock is 258.65M
How many shares of Altimmune, Inc. - Common Stock are outstanding?
Altimmune, Inc. - Common Stock has 259M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap